Premium
Cannabinoid 1 receptor in fatty liver
Author(s) -
Regnell Simon Eringsmark
Publication year - 2013
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2012.01085.x
Subject(s) - cannabinoid , endocannabinoid system , cannabinoid receptor , fatty acid synthesis , steatosis , fatty liver , fatty acid , receptor , sterol regulatory element binding protein , chemistry , pharmacology , biochemistry , transcription factor , biology , medicine , endocrinology , disease , gene , agonist
The role of cannabinoids in fatty liver disease has been increasingly acknowledged in recent years, and it has been suggested that drugs targeting peripheral cannabinoid receptors could have therapeutic use. Development of such drugs would require a good understanding of the mechanisms of fat accumulation caused by cannabinoid receptor activation. This review describes in detail the enzymatic steps that lead from the stimulation of cannabinoid 1 receptor to steatosis. It identifies several signaling pathways that activate sterol regulatory element‐binding protein 1c ( SREBP‐1c ), the key transcription factor causing fatty liver. The downstream effects of SREBP‐1c leading to increased fatty acid synthesis and decreased fatty acid oxidation are also described.